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Abstract  
Background: The CHARM-Preserved trial suggested that the renin-angiotensin system (RAS) 
inhibitor candesartan might have been beneficial in heart failure with preserved ejection fraction 
(HFpEF); however, this hypothesis was not supported by the findings of I-Preserve with irbesartan. 
Aims: To re-analyse the results of I-Preserve, adjusting for imbalances in baseline variables that may 
have influenced the trial outcomes.  
Methods: Cox proportional hazards models with covariate adjustment for baseline variables, including 
age, sex, medical history, physiological and laboratory variables.  
Results: In I-Preserve, 763 (37.0%) participants in the placebo group and 742 (35.9%) in the 
irbesartan group experienced the primary composite outcome (death from any cause or hospitalization 
for heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). The prespecified 
analysis of this outcome, stratifying for use of ACEi at baseline, gave a hazard ratio (HR) of 0.95 
(95% confidence interval, 0.86-1.05); p=0.35. Adjusting the effect of treatment for key prognostic 
baseline variables, gave a HR of 0.89 (0.80-0.99); p=0.033. Similar findings were observed for the 
composite of cardiovascular death or HF hospitalization.  
Conclusion: Adjusting for imbalances in baseline variables that influence outcomes (or the response 
to therapy or both) can improve the power around the estimate of the effect of treatment and may alter 
its statistical significance. Along with the CHARM-Preserved results, these findings suggest that 
angiotensin-receptor blockers may have a modest effect in HFpEF. 
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Although it is commonly stated that heart failure with preserved ejection fraction (HFpEF) is a 
condition for which no treatment has yet been shown to reduce morbidity or mortality, in the 
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-
Preserved trial, fewer individuals treated with candesartan experienced the composite outcome of  a 
first admission to hospital for worsening heart failure or death from cardiovascular causes: 333 
(22.0%) in the candesartan group compared with 366 (24.3%) in the placebo group, giving a hazard 
ratio (HR) of 0.89 (95% CI 0.77–1.03; p=0.118); for first heart failure hospitalization alone, the 
corresponding number were 241 (15.9%) and 276 (18.3%), respectively, giving a HR of 0.85 (0.72-
1.01; p=0.072).1  There was no reduction in cardiovascular death. In a prespecified secondary analysis 
of CHARM-Preserved, baseline characteristics were used to adjust for imbalances in variables that 
might affect outcomes. For the primary composite outcome, the resulting adjusted HR was 0.86 (0.74-
1.00; p=0.051) and for first heart failure hospitalization the adjusted HR was 0.84 (0.70-1.00; 
p=0.047). Coupled with the primary and secondary analyses of the Treatment of Preserved Cardiac 
Function Heart Failure with an Aldosterone Antagonist trial (TOPCAT), these findings suggest that 
blocking the renin-angiotensin-aldosterone system (RAAS) might be beneficial in HFpEF, at least in 
preventing heart failure hospitalization.2-5 However, one large trial appears to be inconsistent with this 
hypothesis i.e. the Irbesartan in patients with heart failure and preserved ejection fraction trial (I-
Preserve) which reported no benefit from irbesartan. There are several potential explanations for this 
discrepancy. First, the hypothesis that RAAS blockade is beneficial in HFpEF could be wrong. 
Second, the primary composite outcome in I-Preserve, which was death from any cause or 
hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, 
arrhythmia, or stroke), was quite different than in CHARM-Preserved and TOPCAT and may have 
been less sensitive to the effect of RAAS-blocking treatment. Third, imbalances in baseline variables 
that might have affected outcomes (or the response to irbesartan or both) were not adjusted for in I-
Preserve, as in the secondary analysis of CHARM-Preserved. We examined these possibilities further 
by conducting a post hoc exploration of the effect of adjusting for a variety of baseline variables on 
the response to treatment with irbesartan in I-Preserve. We also examined the unadjusted and adjusted 
effect of irbesartan on both the prespecified primary outcome in I-Preserve and the narrower, more 
disease-specific, composite outcome used in CHARM-Preserved (which was essentially the same as 
used in TOPCAT). 
 
METHODS 
Study design and objectives 
The design and results of I-Preserve are published. In brief, 4,128 patients who were at least 60 years 
of age and had New York Heart Association (NYHA) functional class II, III, or IV HF and a left 
ventricular ejection fraction (LVEF) of at least 45% and echocardiographic, electrocardiographic or 
radiologic evidence supporting a diagnosis of HF were enrolled. Patients in NYHA functional class II 
were required to have had a HF hospitalization within the previous 6 months. Patients with a systolic 
blood pressure of less than 100 mmHg or more than 160 mmHg or a diastolic blood pressure of more 
than 95 mmHg, were excluded, as were individuals with substantial laboratory abnormalities (such 
as a haemoglobin level of less than 11 g per decilitre, a creatinine level of more than 2.5 mg per 
decilitre [221 µmol per litre], or liver-function abnormalities.  The median follow-up was of 4.1 years. 
In the primary analysis of I-Preserve, no adjustment beyond stratification for angiotensin converting 
enzyme (ACE) inhibitor use at baseline was performed.6  
Statistical analysis 
Cox proportional hazards models stratified for the prior use if angiotensin-converting enzyme 
inhibitors (ACEi) were used as described in the primary analysis of the trial.6, 7 Given the exploratory 
nature of this report, we developed three models adjusting for variables previously used in other I-
Preserve prognostic models and those thought to have potential impact on prognosis and/or the 
treatment effect. The “Model 1” was adjusted for a previously published I-Preserve prognostic 
model,8 that included age, sex, body mass index (BMI), heart rate, systolic blood pressure, 
haemoglobin, estimated glomerular filtration rate (eGFR), atrial fibrillation (AF) on ECG, diabetes 
mellitus, history of chronic obstructive pulmonary disease (COPD) or asthma, history of a myocardial 
infarction (MI), history of hypertension, history of stroke, LVEF, hospitalization for HF in the 
previous 6 months, NYHA class, pulmonary congestion on chest radiograph, presence of jugular 
venous distension, serum albumin (log transformed), serum sodium, and neutrophil count (log 
transformed). Additionally, we built a simplified model (Model 2) using only the variables in Model 1 
that are routinely available in clinical practice9. The variables included in Model 2 were: 1) 
demographics – age and sex; 2) physiological/laboratory measurements - BMI, heart rate, systolic 
blood pressure, haemoglobin, eGFR; 3) medical history – AF on ECG, diabetes mellitus, valvular 
disease, history of COPD or asthma, history of MI, history of stroke and 4) measures of heart failure 
status - LVEF, duration of HF superior to 1 year, hospitalization for HF in the previous 6 months, 
NYHA class III or IV, and pulmonary congestion on chest radiograph. These variables were 
incorporated in a multivariate model ordered by the z-scores of each variable in the model. Finally, 
we built a third model (Model 3), using the variables in model 2 as well as NT-proBNP. Because NT-
pro BNP was not measured in 16% of patients (Supplemental Table 1), we imputed all the variables 
with missing values using chained equations (MICE) and ran the estimates over 20 imputed datasets.10 
We also performed an additional model incorporating the top 5 prognostic variables without missing 
values, and the Model 2 with imputation.     
These variables were reported by investigators by means of check boxes on a case-report 
form or measured as part of the central laboratory investigations in the trial.  
All analyses were performed using STATA (Stata® version 15). A p value <0.05 was 
considered statistically significant. The robust variance estimator was used to compute all the 
presented models.  
 
RESULTS 
Baseline characteristics  
The baseline characteristics of patients in each treatment group are shown in Table 1. The treatment 
groups were generally well matched, with no statistically significant difference between groups. 
However, as discussed below, there were small imbalances between treatment groups in baseline 
variables that might affect outcomes (or the response to irbesartan or both).  
 
Independent predictors of outcome in I-Preserve 
Because Model 2 was the model with the most readily available variables, we focused on this model, 
although the adjusted outcomes for models 1 and 3 are also reported.  The Model 2 variables ordered 
by the strength of the association with the outcome of cardiovascular death or heart failure 
hospitalization, as measured by the z-score, are shown in Table 2. Of the 15 significant variables 
listed (excluding randomized treatment), 11 were slightly more adverse in the irbesartan group (male 
sex, NYHA class, heart rate, LVEF, pulmonary congestion on chest x-ray, previous myocardial 
infarction, diabetes, valvular disease, eGFR below 60 ml/min/1.73m2, duration of heart failure >1 
year, and chronic obstructive pulmonary disease/asthma), 3 were equally distributed between the two 
treatment groups (prior heart failure hospitalization, history of atrial fibrillation, and haemoglobin 
concentration) and one (age) favoured irbesartan.  
 
Effect of irbesartan on the prespecified primary outcome in I-Preserve 
In I-Preserve, 763 (37.0%) participants in the placebo group and 742 (35.9%) in the irbesartan group 
experienced the primary composite outcome (death from any cause or hospitalization for heart failure, 
myocardial infarction, unstable angina, arrhythmia, or stroke). The prespecified analysis of this 
outcome, stratifying for use of ACEi at baseline, gave a hazard ratio (HR) of 0.95 (95% confidence 
interval, 0.86-1.05); p=0.35. Adjusting for the variables in Model 1 or Model 2 each gave an adjusted 
HR of 0.89 (0.80-0.99); p-value =0.033. Adding NT-pro BNP (Model 3) gave an adjusted HR of 0.90 
(0.81-1.00); p-value =0.061 (Table 3). Using only the top five prognostic variables without missing 
data (i.e. HFH in the previous 6 months, age, diabetes, atrial fibrillation and previous MI), the HR 
(95%CI) was 0.95 (0.86-1.04); p-value =0.29. The Model 2 with data imputation gave a HR (95%CI) 
of 0.90 (0.82-1.00); p-value =0.054. 
 
Effect of irbesartan on the composite outcome of cardiovascular death or HF hospitalization 
A substantially smaller number of patients experienced the narrower composite outcome of 
cardiovascular death or HF hospitalization: 533 (25.9%) in the placebo group and 520 (25.2%) in the 
irbesartan group. Analysis of this composite as pre-specified, stratifying for use of ACEi at baseline, 
gave a HR of 0.95 (0.85-1.08); p=0.44. Further adjustment for the additional baseline variables 
described above in Model 1 gave a HR of 0.87 (0.77-0.99); p=0.037, for Model 2 a HR of 0.87 (0.77-
0.99); p=0.039, and for Model 3 a HR of 0.89 (0.79-1.01); p=0.091 (Table 3 & Figure 1). 
  
Effect of irbesartan on heart failure hospitalization and cardiovascular- and all-cause death  
The effect of irbesartan on heart failure hospitalization and on cardiovascular death, individually are 
shown in Table 3. Analysis of heart failure hospitalization alone, stratifying for use of ACEi at 
baseline, gave a HR of 0.95 (0.81-1.10); p=0.50. Adding the Model 1 variables gave a HR of 0.88 
(0.75-1.03); p=0.12, the Model 2 variables a HR of 0.87 (0.74-1.02); p=0.092, and the Model 3 
variables a HR of 0.90 (0.76-1.05); p=0.18. Irbesartan did not reduce the risk of cardiovascular death 
or all-cause death (in the placebo group, 69% of deaths were attributed to cardiovascular causes). 
 
DISCUSSION 
While the effect of irbesartan in the primary prespecified analysis of I-Preserve was “neutral”, our 
post hoc re-analysis of the trial, adjusting for widely available baseline variables, suggested that 
irbesartan could lead to a marginal reduction in both the risk of the original primary composite 
outcome (death from any cause or hospitalization for a cardiovascular cause) and the composite of 
heart failure hospitalization or cardiovascular death (most commonly used endpoint in heart failure 
trials). This marginal reduction reached statistical significance in some of the used models. Although 
post hoc analyses of this type must be interpreted with caution, our study was prompted by a prior, 
prespecified, analysis of CHARM-Preserved, another trial using the same type of treatment (an 
angiotensin receptor blocker) in the same clinical condition (HFpEF). 
Even in large trials, small imbalances in variables which are important determinants of the 
outcomes of interest or of the effect of treatment may occur, by chance, between treatment groups.10 
Such imbalances may lead to inaccurate assessment of the effect of treatment if not accounted for in 
the analysis.10, 11 Therefore, prespecifying that important baseline covariates are included in the 
analysis will mitigate the impact of the potential imbalances between groups in the treatment effect 
estimates.12, 13 Many studies have shown that covariate adjustment of a treatment effect results in 
increased statistical power.11 This gain in statistical power is not only due to correction for potential 
imbalances in baseline covariates between the randomized groups, but also due to the magnitude of 
the prognostic impact of the covariates.14-17 Even when the imbalances are marginal, but the 
prognostic impact or the potential treatment effect modification of the variable is strong, adjustment 
for them may have a significant influence on the estimate of treatment effect.12, 13  Several studies 
have shown that adjustment of this type increases the power around the estimate of the effect of 
treatment and some have advocated that this is done routinely.11 The potential benefits of adjusting for 
a moderate number of prognostically significant variables in trials with a large sample size far 
outweigh any risks of doing so (i.e. the only risk is an increase of the type I error chances when the 
number of adjustment variables is similar to the number of events, which is far from occurring in 
large trials, such as I-Preserve).10 However, despite this, unadjusted analyses dominate in practice; 
only about one-fourth of the trials report covariate adjustment in their main analysis.18 
Notwithstanding, if a large treatment effect is present, this should be observed without adjustment or 
other mathematical modelling. However, in the context of a small treatment effect, covariate 
adjustment may be relevant, especially if there are important differences in baseline characteristics, as 
the result of the play of chance. However, any adjusted analysis, and the variables used in such an 
analysis, should be pre-specified.  
The present post hoc analyses of I-Preserve exemplify some of these considerations. On close 
inspection of the baseline characteristics in the present trial, it can be seen there were slight 
differences between the treatment groups in many of the variables which were independent predictors 
of the outcome of interest. Moreover, of the 15 variables in our simplest predictive model (Model 2), 
an imbalance in 11 of these “favoured” placebo, and only 1 “favoured” irbesartan (with the other 3 
balanced between the treatment groups). Collectively, these imbalances may have altered outcomes in 
the two randomized treatment groups, independently of the effect of irbesartan, and created the 
appearance of an attenuated effect of irbesartan. In other words, the cumulative adverse prognostic 
imbalances in the irbesartan, compared with placebo, may have resulted in a worse outcome in the 
irbesartan group and diminished any benefit of irbesartan. A parallel but more difficult to identify 
issue is whether any of these imbalances might have altered the response to irbesartan (in addition to 
outcomes in the treatment group). Such effects might influence the efficacy or tolerability of 
irbesartan.9  
Our findings highlight the limitations of relying on an arbitrary p-value to determine whether 
a trial is “positive” or not.  Our data show that a p-value can vary from 0.2 to 0.05 or less, depending 
on whether or not adjustment is performed and if so, what variables are used.  
In addition to exemplifying the potential value of adjusting the analysis of treatment effect in 
randomized trials, our findings suggest that RAAS blockade does have at least a modest benefit in 
patients with HFpEF and that I-Preserve and CHARM-Preserved do not differ to the extent previously 
assumed. If correct, this is clinically important for a condition without any other effective therapy. 
Moreover, the potential benefit of angiotensin-receptor blockers in patients with HFpEF may have 
contributed to the smaller-than-anticipated treatment difference between the treatment groups in the 
PARAGON-HF trial.19 
Limitations 
The main limitation in our study is that the covariate adjustment was not prespecified, hence this 
analysis should be regarded as exploratory. In addition, the gain in treatment effect-size resulting from 
covariate adjustment was somewhat larger than previously observed and may not be typical of what 
might be expected. We showed and additional relative risk reduction of 6 to 7% for each of the 
original primary composite outcome and the more typically used composite of heart failure 
hospitalization or cardiovascular death. In HF-ACTION, adjustment led to a 4% further reduction in 
the hazard ratio for the primary outcome in favour of exercise training (HR from 0.93 to 0.89) with a 
statistically significant treatment effect apparent only after adjustment.16  In EMPHASIS-HF the 
prespecified covariate adjustment gave a 3% further reduction in the hazard ratio for the primary 
outcome in favour of eplerenone (HR from 0.66 to 0.63).20 In GISSI-HF, covariate adjustment led to a 
2% further reduction in the hazard ratio for the co-primary endpoints in favour of n-3 polyunsaturated 
fatty acid therapy (resulting in both becoming statistically significant, compared with the unadjusted 
analysis).17 Importantly, it is essential that a covariate-adjusted approach is pre-specified, based upon 
existing knowledge. Covariate adjustment performed after knowledge of the trial findings (as 
performed in this retrospective analysis) increases bias and limits the external validity of the 
findings.21 Some important considerations on covariate adjustment are described in the Figure 2.  
 
Conclusion 
Slight imbalances in baseline variables which influence trial endpoints (and, potentially, the effect of 
the therapy under investigation) may occur, by chance, even in large randomized clinical trials. 
Correcting for these variables may increase the power of the treatment effect estimate. Along with the 
CHARM-Preserved results, these findings suggest that angiotensin-receptor blockers may have a 
modest benefit in HFpEF, which could have contributed to the smaller-than-anticipated difference 
between treatment groups in the PARAGON-HF trial. However, this inference must remain 
speculative, given the exploratory, post hoc, nature of our analyses. 
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Table 1. Comparison of the baseline patients` characteristics by treatment allocation 
Clinical characteristics Placebo Irbesartan p-value 
N. 2061 2067 - 
Age, yr 71.7 ± 7.0 71.6 ± 6.9 0.61 
    Age ≥75 yr 716 (34.7%) 697 (33.7%) 0.49 
Female sex 1264 (61.3%) 1227 (59.4%) 0.20 
White race 1925 (93.4%) 1934 (93.6%) 0.79 
NYHA class III/IV 1615 (78.4%) 1641 (79.4%) 0.44 
Heart rate, bpm 71.2 ± 10.3 71.7 ± 10.6 0.16 
    Heart rate >70bpm 1026 (49.8%) 1033 (50.0%) 0.90 
SBP, mmHg 136.0 ± 15.0 136.7 ± 15.0 0.10 
    SBP <120 mmHg 210 (10.2%) 194 (9.4%)  
    SBP 120-140 mmHg 1216 (59.0%) 1167 (56.5%) 0.067 
    SBP >140 mmHg 635 (30.8%) 706 (34.2%)  
BMI, Kg/m2 29.6 ± 5.3 29.7 ± 5.3 0.46 
    BMI <25 Kg/m2 358 (17.5%) 321 (15.6%)  
    BMI 25-35 Kg/m2 1402 (68.3%) 1432 (69.6%) 0.28 
    BMI >35 Kg/m2 292 (14.2%) 304 (14.8%)  
LVEF, % 59.5 ± 9.0 59.4 ± 9.3 0.62 
    LVEF ≤50% 406 (19.7%) 434 (21.0%) 0.30 
Pulm. congestion CXR 782 (39.6%) 808 (40.5%) 0.54 
Cause of HF   0.44 
    Ischaemia 500 (24.3%) 536 (25.9%)  
    Hypertension  1304 (63.3%) 1318 (63.8%)  
HF duration >1 year 1048 (50.9%) 1079 (52.2%) 0.39 
HFH prev. 6 months 906 (44.0%) 910 (44.0%) 0.97 
Myocardial infarction  482 (23.4%) 487 (23.6%) 0.90 
Hypertension  1816 (88.1%) 1834 (88.7%) 0.54 
Atrial fibrillation  603 (29.3%) 606 (29.3%) 0.97 
Diabetes 564 (27.4%) 570 (27.6%) 0.88 
Valvular disease  220 (10.7%) 231 (11.2%) 0.61 
COPD/Asthma 188 (9.1%) 203 (9.8%) 0.44 
Stroke  201 (9.8%) 198 (9.6%) 0.85 
Hemoglobin, g/dL 14.0 ± 1.5 14.0 ± 1.5 0.77 
    Hemoglobin ≤12 g/dL 174 (8.7%) 166 (8.3%) 0.69 
eGFR, ml/min 72.5 ± 22.4 72.6 ± 22.6 0.88 
    eGFR ≥60 ml/min 1406 (69.6%) 1387 (68.7%)  
    eGFR 45-59 ml/min 417 (20.7%) 427 (21.2%) 0.80 
    eGFR <45 ml/min 196 (9.7%) 205 (10.2%)  
Sodium, mmol/L 139.5 ± 3.0 139.5 ± 3.0 0.93 
Potassium, mmol/L 4.5 ± 0.5 4.4 ± 0.5 0.20 
Neutrophils, 10^3 cells/µL 4.5 ± 1.8 4.5 ± 1.7 0.75 
NT-pro BNP, pg/mL 320 (131-946) 360 (138-987) 0.30 
Treatment    
ACEi 501 (24.8%) 538 (26.0%) 0.34 
Beta-blocker 1202 (58.3%) 1225 (59.3%) 0.53 
Calcium channel blocker 811 (39.4%) 826 (40.0%) 0.68 
Loop diuretic 1071 (52.0%) 1079 (52.3%) 0.87 
Spironolactone 313 (15.2%) 320 (15.5%) 0.79 
Lipid-lowering treatment 622 (30.2%) 657 (31.8%) 0.26 
Antiplatelet agent 1193 (57.9%) 1223 (59.2%) 0.39 
Legend: Pulm., pulmonary ; ACEi, angiotensin converting enzyme inhibitor; CXR, chest x-ray; SBP, systolic 
blood pressure; BMI, body mass index; LVEF, left ventricular ejection fraction; HFH, heart failure 
hospitalization; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; 
NT-pro BNP, N-terminal pro brain natriuretic peptide; ACEi, angiotensin-converting enzyme inhibitor.  
 
 
Table 2. Prognostic importance of the baseline clinical variables (for the outcome of cardiovascular 
death or heart failure hospitalization) 
Variable HR (95%CI) z-score P-value 
HFH prev. 6 months 2.18 (1.87-2.54) 10.0 <0.001 
Age (per yr) 1.05 (1.04-1.06) 8.7 <0.001 
Diabetes 1.69 (1.48-1.93) 7.6 <0.001 
Atrial fibrillation 1.43 (1.25-1.64) 5.2 <0.001 
LVEF (per %) 0.98 (0.97-0.99) -4.8 <0.001 
Heart rate (per bpm) 1.01 (1.01-1.02) 4.6 <0.001 
Previous MI 1.37 (1.19-1.59) 4.3 <0.001 
eGFR (per ml/min) 0.99 (0.99-1.00) -4.2 <0.001 
Pulm. congestion CXR 1.29 (1.13-1.47) 3.8 <0.001 
COPD/Asthma 1.44 (1.20-1.73) 3.9 <0.001 
Male sex 1.27 (1.11-1.45) 3.4 0.001 
Hb (per g/dL) 0.93 (0.89-0.97) -3.3 0.001 
NYHA III/IV 1.31 (1.11-1.54) 3.2 0.002 
HF diagnosis >1yr 1.21 (1.06-1.38) 2.8 0.005 
Valvular disease 1.22 (1.02-1.46) 2.2 0.027 
Stroke history 1.19 (0.98-1.43) 1.8 0.075 
BMI (per Kg/m2) 1.01 (1.00-1.02) 1.6 0.11 
SBP (per mmHg) 1.00 (1.00-1.00) -0.2 0.83 
Irbesartan (vs. Placebo) 0.87 (0.77-0.99) -2.1 0.035 
Legend: HF, heart failure; HFH, heart failure hospitalization; pulm., pulmonary; prev., previous; CXR, chest x-
ray; COPD, chronic obstructive pulmonary disease; Hb, haemoglobin; BMI, body mass index; MI, myocardial 
infarction; NYHA, New York Heart Association; SBP, systolic blood pressure. 
The p-values presented in this table are p-values from the multivariate models.  
 
 





HR (95%CI) p-value 
Primary outcome 
Prespecified analysis 0.95 (0.86-1.05) 0.35 
Model 1 0.89 (0.80-0.99) 0.033 
Model 2 0.89 (0.80-0.99) 0.033 
Model 3 
763 (37.0%) 742 (35.9%) 
0.91 (0.82-1.00) 0.061 
CV death or HFH 
Prespecified analysis 0.95 (0.85-1.08) 0.44 
Model 1 0.87 (0.77-0.99) 0.037 
Model 2 0.87 (0.77-0.99) 0.039 
Model 3 
533 (25.9%) 520 (25.2%) 
0.90 (0.79-1.02) 0.091 
HFH alone 
Prespecified analysis 0.95 (0.81-1.10) 0.50 
Model 1 0.88 (0.75-1.03) 0.12 
Model 2 0.87 (0.74-1.02) 0.092 
Model 3 
336 (16.3%) 325 (15.7%) 
0.90 (0.76-1.05) 0.18 
CV death 
Prespecified analysis 1.01 (0.86-1.18) 0.92 
Model 1 0.92 (0.78-1.09) 0.33 
Model 2 0.92 (0.78-1.09) 0.32 
Model 3 
302 (14.7%) 311 (15.1%) 
0.93 (0.79-1.09) 0.38 
All-cause death 
Prespecified analysis 1.00 (0.88-1.14) 0.98 
Model 1 0.93 (0.81-1.07) 0.30 
Model 2 
436 (21.2%) 445 (21.5%) 
0.94 (0.81-1.07) 0.35 
Model 3   0.93 (0.81-1.07) 0.30 
Prespecified analysis: Cox proportional hazards models stratified for the prior use if angiotensin-converting 
enzyme inhibitors (ACEi). 
Model 1, study treatment adjusted on age, sex, atrial fibrillation, diabetes mellitus, previous myocardial 
infarction, hypertension, COPD, HFH in the previous 6 months, presence of jugular venous distension, NYHA 
class III or IV, pulmonary congestion on chest radiograph, LVEF, BMI, heart rate, haemoglobin, eGFR, serum 
sodium, albumin, and neutrophils (model used in Jhund P. et al. Changes in N-terminal pro-B-type natriuretic 
peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve 
study. Eur J Heart Fail. 2015). 
Model 2, study treatment effect adjusted on age, sex, atrial fibrillation, diabetes mellitus, previous myocardial 
infarction, valvular disease, COPD, HFH in the previous 6 months, HF duration > 1 year, NYHA class III or 
IV, pulmonary congestion on chest radiograph, LVEF, BMI, heart rate, systolic blood pressure, haemoglobin, 
eGFR (“clinical model”; see also Table 2).  
Model 3, Model 2 plus NT-pro BNP with multiple imputation for all the variables with any missing value in the 
model.  
Note: The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause 
(heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke).   
All models with stratification factor on the use of ACEi at baseline. 
Legend: CV, cardiovascular; HFH, hospitalization for heart failure; AFib, atrial fibrillation; COPD, chronic 
obstructive pulmonary disease; BMI, body mass index; LVEF, left ventricular ejection fraction; eGFR, 
estimated glomerular filtration rate.  
 
Figure 1. Adjusted cumulative hazard curve for the outcome of cardiovascular death or heart failure 
hospitalization 
(A) Unadjusted model 
 
(B) Adjusted model* 
 
*Adjusted: study treatment effect adjusted on age, sex, atrial fibrillation, diabetes mellitus, previous myocardial 
infarction, valvular disease, COPD, HFH in the previous 6 months, HF duration > 1 year, NYHA class III or 
IV, pulmonary congestion on chest radiograph, LVEF, BMI, heart rate, systolic blood pressure, haemoglobin, 
eGFR (“Model 2”; see also Table 3). P-value for treatment effect in (A) =0.44 and in (B) =0.039. 
Figure 2. Covariate adjustment in RCTs 
 
 
